Assenagon Asset Management S.A. Sells 188,423 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Assenagon Asset Management S.A. decreased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 52.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 173,714 shares of the specialty pharmaceutical company's stock after selling 188,423 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.53% of Collegium Pharmaceutical worth $6,712,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Gladius Capital Management LP acquired a new stake in Collegium Pharmaceutical during the second quarter worth about $32,000. GAMMA Investing LLC raised its holdings in Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock valued at $55,000 after buying an additional 792 shares during the period. CWM LLC raised its holdings in Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock valued at $58,000 after buying an additional 736 shares during the period. nVerses Capital LLC lifted its position in Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company's stock valued at $55,000 after buying an additional 1,600 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC purchased a new stake in Collegium Pharmaceutical during the first quarter worth approximately $204,000.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the business's stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares in the company, valued at $4,602,166.30. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Thomas B. Smith sold 9,593 shares of the firm's stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now directly owns 53,816 shares in the company, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the sale, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.98% of the company's stock.

Analysts Set New Price Targets

COLL has been the topic of several recent research reports. Piper Sandler restated a "neutral" rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. HC Wainwright boosted their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a research note on Thursday, September 5th. Truist Financial increased their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Friday, August 9th. StockNews.com lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, October 23rd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $42.60.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock traded up $0.11 during mid-day trading on Tuesday, reaching $35.24. The company's stock had a trading volume of 311,848 shares, compared to its average volume of 441,322. The company has a current ratio of 1.11, a quick ratio of 1.04 and a debt-to-equity ratio of 1.71. Collegium Pharmaceutical, Inc. has a twelve month low of $21.11 and a twelve month high of $42.29. The business has a 50 day moving average price of $37.64 and a 200-day moving average price of $35.29. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of 14.70 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The business had revenue of $145.28 million during the quarter, compared to analyst estimates of $143.94 million. During the same period in the previous year, the business posted $1.13 EPS. The company's quarterly revenue was up 7.2% on a year-over-year basis. Sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.79 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.